Topic
Off-label Drug Use
134 published works
Drug & Device Law
Non-Patent Implications of Supreme Court’s “Skinny Label” Hikma Decision
By Bexis
We don’t normally discuss patent/intellectual property issues on the Blog, even though they arise all the time in prescription medical product litigation. The reason is simple − our clients (and…
Drug & Device Law
Off-Label Notes
By Bexis
The Blog has always been interested in off-label use issues. We hope our readers are as well. Here are a couple of recent developments that have nothing in common except…
Drug & Device Law
Off-Label Prescribing Is Not A Crime
By Lisa Baird
Today’s post is about one of our favorite topics, off-label use. This time, it isn't about what manufacturers can say about unapproved uses. It's about whether the DOJ can wield…
Patent Law Weblog
Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs – Part II
By Kevin E. Noonan – In recent years, the Federal Circuit has, with varying levels of agreement, considered what behavior by generic drugmakers constitutes inducement of infringement regarding so-called “off-label”…
Drug & Device Law
Once More Into the Breach on Off-Label Use
By Bexis
Some of us are old enough to remember when the Kessler-led FDA attacked off-label use of prescription medical products by using archaic language in the agency’s “intended use” regulations (21…
Drug & Device Law
FCA Dismissal Illustrates Pharmaceutical Promotion Done Right
By Bexis
Back in the bad old days of the Bone Screw litigation, we had to fight our way through a thicket of scurrilous allegations about how our clients supposedly promoted off-label…
Drug & Device Law
On Banning Off-Label Uses
By Bexis
In his latest off-label use-related law review article in 2021, Bexis pointed out: [A]lthough states have traditionally been recognized to have broad authority to regulate the practice of medicine, aside…
Health Care and Life Sciences
DOJ Targets Gender‑Affirming Care under FDCA and FCA: Scrutinizes Off‑Label Drug Use and False Diagnosis Codes
By Matthew J. Westbrook, Jonian Rafti, Vinay Kohli, Jason Madden, David Manko
Last month, the United States Department of Justice (“DOJ”) issued its “Civil Division Enforcement Priorities” memorandum, memorializing a shift from its predecessor administration’s policy on gender‑affirming healthcare (“DOJ Memo”). The…
Drug & Device Law
The January 6, 2025 Final Guidance On Off-Label Use
By Lisa Baird
“Off label use” is a bit of an odd thing. The FDA does not regulate the practice of medicine, but it does get involved in the labeling of medical devices…
Drug & Device Law
Package Inserts Are Not Admissible to Establish Standard of Care
By Eric Hudson
We consistently defend the ability of physicians to engage in off-label use. Bexis helped lay the scholarly foundation for courts to utilize the term “off label use,” and two of…